Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

Stock Information for Lifecore Biomedical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lifecore Biomedical Inc.

Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Settles
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Notice to Long-Term Shareholders of Ibotta, Inc. (NYSE: IBTA); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Varonis Systems, Inc. (NASDAQ: VRNS): Grabar Law Office Investigates Claims on Your Behalf
Notice to Long-Term Shareholders of Ibatta, Inc. (NYSE: IBTA); Integer Holdings Corp, (NYSE: ITGR); Lifecore Biomedical, Inc. (NASDAQ: LFCR); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Behalf
Notice to Long-Term Shareholders of CoreWeave, Inc. (NASDAQ: CRWV); Integer Holdings Corp, (NYSE: ITGR); Lifecore Biomedical, Inc. (NASDAQ: LFCR); and Varonis Systems, Inc. (NASDAQ: VRNS): Grabar Law Office Investigates Claims on Your Behalf
Notice to Long-Term Shareholders of Ibotta, Inc. (NYSE: IBTA); Integer Holdings Corp, (NYSE: ITGR); Lifecore Biomedical, Inc. (NASDAQ: LFCR); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Behalf
Attention Long-Term Shareholders of Ibotta, Inc. (NYSE: IBTA); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.